文献速递脊柱外科骨质疏松与代谢性骨病

维生素D3能否预防万古霉素对成骨细胞的抑制作用?

Does Vitamin D3 Prevent the Inhibitory Effect of Vancomycin on Osteoblasts?
PubMed 文献 · Clin Orthop Relat Res · 2020-01-01

本研究在MC3T3-E1成骨细胞培养中探讨高浓度万古霉素的细胞毒性及维生素D3的保护作用。结果显示7500 μg/mL万古霉素显著减少活成骨细胞数量,持续给药时维生素D3无保护效应,但脉冲式给药24小时后维生素D3可恢复细胞数量及矿化染色。

要点

  • 7500 μg/mL万古霉素持续或脉冲给药均显著降低成骨细胞数量。
  • 持续给药时添加0.01 nM维生素D3未显示保护作用。
  • 脉冲给药24小时后维生素D3可恢复细胞数量及矿化染色。

核心结论

  • 7500 μg/mL万古霉素对成骨细胞具有细胞毒性。
  • 脉冲式给药24小时后联合维生素D3可预防该细胞毒性。

研究设计与样本

  • 体外研究,使用MC3T3-E1成骨细胞系。
  • 万古霉素浓度设为2500、5000、7500 μg/mL,维生素D3浓度为0.01 nM。
  • 分为持续给药组(测6、12、24、72小时)和脉冲给药24小时组(测1、3、7天)。

主要发现

  • 持续7500 μg/mL万古霉素在72小时细胞数:对照组14.6×10 cells/mL ± 0.260×10 cells/mL,万古霉素组0.917×10 cells/mL ± 0.288×10 cells/mL,均数差-13.7×10 cells/mL ± 0.388×10 cells/mL(95% CI -14.5至-12.9),p < 0.001。
  • 持续7500 μg/mL万古霉素加维生素D3在72小时细胞数:万古霉素单用组0.917×10 cells/mL ± 0.288×10 cells/mL,联合组1.67×10 cells/mL ± 0.310×10 cells/mL,均数差0.75×10 cells/mL ± 0.423×10 cells/mL(95% CI -0.127至1.63),p = 0.09。
  • 脉冲7500 μg/mL万古霉素在7天细胞数:对照组18.6×10 cells/mL ± 1.29×10 cells/mL,万古霉素组3.46×10 cells/mL ± 0.292×10 cells/mL,均数差-15.1×10 cells/mL ± 1.33×10 cells/mL(95% CI -17.9至-12.4),p < 0.001。
  • 脉冲7500 μg/mL万古霉素加维生素D3在7天细胞数:万古霉素单用组3.46×10 cells/mL ± 0.292×10 cells/mL,联合组10.6×10 cells/mL ± 0.900×10 cells/mL,均数差7.13×10 cells/mL ± 0.946×10 cells/mL(95% CI 5.16至9.09),p < 0.001。
  • 基因表达:I型胶原(万古霉素单用0.319 ± 0.0730,联合0.511 ± 0.139,均数差0.192 ± 0.157,95% CI -0.483至0.867,p = 0.345)、碱性磷酸酶(0.532 ± 0.0210 vs 0.785 ± 0.0590,均数差0.253 ± 0.0620,95% CI -0.0150至0.521,p = 0.0550)、cathelicidin抗菌肽(0.885 ± 0.0520 vs 1.24 ± 0.125,均数差0.355 ± 0.135,95% CI -0.0200至0.730,p = 0.0580)均无显著差异。

关键数值与推荐

  • 万古霉素对成骨细胞的细胞毒性浓度:7500 μg/mL。
  • 维生素D3保护效应仅在脉冲给药24小时条件下观察到。

临床怎么用

  • 临床常用高浓度万古霉素可能对成骨细胞产生毒性,或与脊柱术后假关节形成相关。
  • 脉冲式局部应用万古霉素时,联合维生素D3可能减轻成骨细胞毒性。

局限性

  • 仅为体外细胞实验,结果需临床研究验证。
  • 维生素D3的最佳剂量及给药方案未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The utility of vancomycin powder to prevent surgical site infection, mainly in spinal surgery, has been widely examined, and the local administration of vancomycin powder to wounds has been reported to be effective in preventing surgical site infections after spine surgery. However, in vitro studies have shown that high local concentrations of vancomycin may inhibit osteogenesis, although it remains unclear how these high concentrations influence osteoblasts. No candidate drug has been reported to recover cytotoxicity with high concentrations of vancomycin, but we suggest that vitamin D3, which induces osteoblast proliferation, may be administrated concomitantly with vancomycin in these situations. QUESTIONS/PURPOSES: (1) Does a high concentration of vancomycin reduce viable osteoblast numbers in cell culture compared with controls? (2) Does vitamin D3 administration confer a protective effect on osteoblasts when administered with continuous vancomycin? (3) Does vitamin D3 administration confer a protective effect on osteoblasts when administered with pulsed vancomycin (24 hours of administration)? (4) Does vitamin D3 administration confer alkaline phosphatase, mineralization, and gene expression when administered with pulsed vancomycin? METHODS: MC3T3-E1 cells were cultured at 37° C in an α-minimum essential medium supplemented with 10% fetal bovine serum in a humidified incubator containing 5% CO2. The experimental concentrations of vancomycin (2500 μg/mL, 5000 μg/mL, and 7500 μg/mL) were determined based on previous reports and preliminary experiments. We concomitantly administered vitamin D3 (0.01 nM) to prevent cytotoxicity in osteoblasts, using two different treatments: continuous vancomycin administration (measured at 6 hours, 12 hours, 24 hours, and 72 hours) and pulsed vancomycin for 24 hours (measured at 1 days, 3 days, and 7 days). We analyzed cell numbers and morphologic changes in cells treated with vancomycin or vancomycin plus 0.01 nM vitamin D3. Osteoblast differentiation was assessed with alkaline phosphatase staining, alkaline phosphatase activity, and Alizarin red S staining. RESULTS: The number of cells was reduced at 6 hours, 24 hours, 48 hours, and 72 hours in response to continuous vancomycin administration at 7500 µg/mL (at 72 hours, control 14.6 × 10 cells/mL ± 0.260 × 10 cells/mL, vancomycin at 0.917 × 10 cells/mL ± 0.288 × 10 cells/mL, mean difference -13.7 × 10 cells/mL ± 0.388 × 10 cells/mL [95% CI -14.5 to -12.9]; p < 0.001). Vitamin D3 did not have a protective effect when vancomycin was administered continuously at 7500 µg/mL (at 72 hours, vancomycin alone 0.917 × 10 cells/mL ± 0.288 × 10 cells/mL, vancomycin + vitamin D3 1.67 × 10 cells/mL ± 0.310 × 10 cells/mL, mean difference 0.75 × 10 cells/mL ± 0.423 × 10 cells/mL [95% CI -0.127 to 1.63]; p = 0.09).With pulsed administration for only the first 24 hours, the number of cells was reduced at 1 day, 3 days, and 7 days at 7500 μg/mL (at 7 days, control 18.6 × 10 cells/mL ± 1.29 × 10 cells/mL, vancomycin at 3.46 × 10 cells/mL ± 0.292 × 10 cells/mL, mean difference -15.1 × 10 cells/mL ±1.33 × 10 cells/mL [95% CI -17.9 to -12.4]; p < 0.001 for all). However, vitamin D3 had a recovery effect when vancomycin was administered only for 24 hours (cell number with 7500 μg/mL, day 7: vancomycin alone 3.46 × 10 cells/mL ± 0.292 × 10 cells/mL, vancomycin +vitamin D3 10.6 × 10 cells/mL ± 0.900 × 10 cells/mL, mean difference 7.13 × 10 cells/mL ± 0.946 × 10 cells/mL [95% CI 5.16 to 9.09]; p < 0.001).With the addition of vitamin D3, we observed recovery of alkaline phosphatase staining and Alizarin red staining (evidence of calcification) but no difference in the gene expression of Type I collagen (vancomycin alone 0.319 ± 0.0730, vancomycin + vitamin D3 0.511 ± 0.139, mean difference 0.192 ± 0.157 [95% CI -0.483 to 0.867]; p = 0.345), alkaline phosphatase (vancomycin alone 0.532 ± 0.0210, vancomycin + vitamin D3 0.785 ± 0.0590, mean difference 0.253 ± 0.0620 [95% CI -0.0150 to 0.521]; p = 0.0550), and cathelicidin antimicrobial peptide (vancomycin alone 0.885 ± 0.0520, vancomycin + vitamin D3 1.24 ± 0.125, mean difference 0.355 ± 0.135 [95% CI -0.0200 to 0.730]; p = 0.0580). CONCLUSION: We found that 7500 µg/mL of vancomycin is cytotoxic to osteoblasts. Cytotoxicity could be prevented by administering vitamin D3 in combination with vancomycin. CLINICAL RELEVANCE: The high concentrations of vancomycin routinely used clinically raises concerns related to osteoblast cytotoxicity, which may contribute to pseudoarthrosis after spinal surgery. Thus, vitamin D3, which is frequently used to treat osteoporosis, may have efficacy as a concomitantly administered drug by inducing the proliferation of osteoblasts. These results indicate that a combination therapy of vancomycin and vitamin D3 may prevent adverse events such as osteoblast cytotoxicity.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Tsuji K, Kimura S, Tateda K, et al. Does Vitamin D3 Prevent the Inhibitory Effect of Vancomycin on Osteoblasts? Clin Orthop Relat Res. 2020. PMID: 31794484. doi:10.1097/CORR.0000000000001060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。